Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ElLen phase 3 trial in newly diagnosed transplant-eligible multiple myeloma
2024-516418-39-00Phase 3Authorised
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- Jul 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of elranatamab and lenalidomide in multiple myeloma (MM) (4 arms), sponsored by Inter-Groupe Francophone du Myélome. Primary endpoints: MRD negativity rate at end of consolidation and PFS R2. Planned start Jul 2025; status: authorised.
02
Drugs
elranatamablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516418-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516418-39-00.